2024
How I treat challenging transfusion cases in sickle cell disease
Chou S, Hendrickson J. How I treat challenging transfusion cases in sickle cell disease. Blood 2024 PMID: 38728382, DOI: 10.1182/blood.2023023648.Peer-Reviewed Original ResearchDelayed hemolytic transfusion reactionSickle cell diseaseRed blood cellsTransfusion of red blood cellsRed blood cell alloantibodiesRed blood cell transfusionCell diseaseHemolytic transfusion reactionsManagement of complicationsAlloimmunized patientsRh alloimmunizationCurative therapyTransfusion guidelinesTransfusion recipientsClinical dilemmaFuture transfusionsTransfusionPatient populationTransfusion casesTransfusion reactionsBlood donorsRH variantsBlood cellsAlloimmunizationMedicine providers
2023
Associations of donor, component, and recipient factors on hemoglobin increments following red blood cell transfusion in very low birth weight infants
DeSimone R, Plimier C, Goel R, Hendrickson J, Josephson C, Patel R, Sola‐Visner M, Roubinian N. Associations of donor, component, and recipient factors on hemoglobin increments following red blood cell transfusion in very low birth weight infants. Transfusion 2023, 63: 1424-1429. PMID: 37387597, PMCID: PMC10530070, DOI: 10.1111/trf.17468.Peer-Reviewed Original ResearchConceptsLow birth weight infantsRed blood cell transfusionBirth weight infantsBlood cell transfusionVLBW infantsHemoglobin incrementsTransfusion effectivenessCell transfusionWeight infantsRBC transfusionHemoglobin levelsRecipient factorsBlood donorsSingle-unit RBC transfusionsRBC unitsAssociation of donorDonor hemoglobin levelsTransfusion episodesTransfusion eventsClinical outcomesDonor factorsMultivariable regressionTransfusionDonor sexFemale donors
2022
FcγRIV is required for IgG2c mediated enhancement of RBC alloimmunization
Qiu A, Miller A, Dei Zotti F, Santhanakrishnan M, Hendrickson JE, Tredicine M, Stowell SR, Luckey CJ, Zimring JC, Hudson KE. FcγRIV is required for IgG2c mediated enhancement of RBC alloimmunization. Frontiers In Immunology 2022, 13: 972723. PMID: 36189253, PMCID: PMC9519184, DOI: 10.3389/fimmu.2022.972723.Peer-Reviewed Original ResearchConceptsAlloantibody productionRBC alloimmunizationPassive immunizationRBC clearanceSplenic dendritic cell subsetsRed blood cell transfusionSplenic conventional DCsBlood cell transfusionDendritic cell subsetsConventional DCsFc gamma receptorsHumoral alloimmunizationAlloantibody responsesCell transfusionMaternal alloimmunizationCell subsetsFcγR expressionIgG antibodiesHemolytic diseaseBlocking antibodiesAlloimmunizationImmune complexesMouse modelKnockout miceAntibodiesTransfusion in infants and children
Hendrickson J, Josephson C. Transfusion in infants and children. 2022, 381-391. DOI: 10.1002/9781119719809.ch34.Peer-Reviewed Original ResearchRed blood cell transfusionGraft-versushost diseaseEtiology of anemiaBlood cell transfusionRisk of thrombosisSequestration of plateletsPotential adverse effectsActive bleedingCell transfusionPreterm infantsTransfusion supportCryoprecipitate transfusionOxygen-carrying capacityPediatric patientsPlatelet transfusionsTransfusionFactor VIIIThrombocytopeniaDecreased productionInfantsThawed plasmaAdverse effectsFactor XIIIAcellular productsChildrenClodronate inhibits alloimmunization against distinct red blood cell alloantigens in mice
Arthur CM, Patel SR, Sharma A, Zerra PE, Chonat S, Jajosky RP, Fasano RM, Patel R, Bennett A, Zhou X, Luckey CJ, Hudson KE, Eisenbarth SC, Josephson CD, Roback JD, Hendrickson JE, Stowell SR. Clodronate inhibits alloimmunization against distinct red blood cell alloantigens in mice. Transfusion 2022, 62: 948-953. PMID: 35470900, PMCID: PMC9491148, DOI: 10.1111/trf.16872.Peer-Reviewed Original ResearchConceptsRBC alloimmunizationRBC transfusionAntibody formationPreclinical modelsRed blood cell transfusionBlood cell alloantigensBlood cell transfusionTransfusion of RBCsTransfusion-dependent patientsDevelopment of alloantibodiesIgG antibody formationAlloantigen exposureHOD RBCsCell transfusionPost transfusionAlloantibody formationPharmacological removalIgG antibodiesTransfusionAlloimmunizationClodronateMarginal sinusPrior treatmentDay 5KEL antigenInternational guidelines regarding the role of IVIG in the management of Rh‐ and ABO‐mediated haemolytic disease of the newborn
Lieberman L, Lopriore E, Baker JM, Bercovitz RS, Christensen RD, Crighton G, Delaney M, Goel R, Hendrickson JE, Keir A, Landry D, La Rocca U, Lemyre B, Maier RF, Muniz‐Diaz E, Nahirniak S, New HV, Pavenski K, dos Santos M, Ramsey G, Shehata N, Guidelines F. International guidelines regarding the role of IVIG in the management of Rh‐ and ABO‐mediated haemolytic disease of the newborn. British Journal Of Haematology 2022, 198: 183-195. PMID: 35415922, PMCID: PMC9324942, DOI: 10.1111/bjh.18170.Peer-Reviewed Original ResearchConceptsRole of IVIGIntravenous immunoglobulinExchange transfusionHaemolytic diseaseSafety of IVIGRed blood cell transfusionBlood cell transfusionDuration of hospitalizationSeverity of anemiaEvidence-based recommendationsHigh-quality studiesCell transfusionPrompt treatmentBilirubin levelsSignificant morbidityAlternative therapiesIntensive phototherapyNeurocognitive outcomesManagement of RhInternational guidelinesTransfusionNewbornsDiseasePhototherapyInternational panel
2021
Management of hemolytic transfusion reactions
Hendrickson JE, Fasano RM. Management of hemolytic transfusion reactions. Hematology 2021, 2021: 704-709. PMID: 34889404, PMCID: PMC8791106, DOI: 10.1182/hematology.2021000308.Peer-Reviewed Original ResearchConceptsHemolytic transfusion reactionsRBC alloantibodiesSevere DHTRTransfusion reactionsRed blood cell transfusionDisease-specific risk factorsPathway activationMultiple RBC alloantibodiesBlood cell transfusionSymptoms of painStem cell transplantationSafety of transfusionSickle cell diseaseClassic pathway activationAlternative pathway activationTransfusion avoidanceCell transfusionCurative therapyCell transplantationPatient's hemoglobinRisk factorsTransfusion safetyCell diseaseDHTRHgb ANon-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy
Curtis SA, Raisa BM, Roberts JD, Hendrickson JE, Starrels J, Lesley D, Michelle D, Daniel Z, Brandow AM. Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy. Transfusion And Apheresis Science 2021, 61: 103304. PMID: 34782244, PMCID: PMC9838733, DOI: 10.1016/j.transci.2021.103304.Peer-Reviewed Original ResearchConceptsChronic exchange transfusionsHealth care utilizationCare utilizationExchange transfusionPain impactDisease characteristicsChronic red blood cell transfusionsRed blood cell transfusionLower health care utilizationSickle Cell Disease PainExchange transfusion therapyAcute care utilizationBlood cell transfusionSimilar disease characteristicsPatient-reported outcomesLength of staySickle cell diseaseQuality of lifeCause admissionsCell transfusionNeuropathic painOpioid prescriptionsWorst painAcute painAdult patientsMarginal zone B cells mediate a CD4 T-cell–dependent extrafollicular antibody response following RBC transfusion in mice
Zerra PE, Patel SR, Jajosky RP, Arthur CM, McCoy JW, Allen JWL, Chonat S, Fasano RM, Roback JD, Josephson CD, Hendrickson J, Stowell SR. Marginal zone B cells mediate a CD4 T-cell–dependent extrafollicular antibody response following RBC transfusion in mice. Blood 2021, 138: 706-721. PMID: 33876205, PMCID: PMC8394907, DOI: 10.1182/blood.2020009376.Peer-Reviewed Original ResearchConceptsMarginal zone B cellsRBC transfusionMZ B cellsB cellsHOD RBCsAlloantibody formationAntibody responseAntibody formationAntigen-specific germinal center B cellsB cell-deficient recipientsCD4 T-cell depletionRed blood cell transfusionCD4 T cell activationRBC alloantibody formationBlood cell transfusionT-cell depletionCD4 T cellsProbability of complicationsExtrafollicular antibody responsesGerminal center B cellsFollicular B cellsT cell activationRBC alloimmunizationCell transfusionSubsequent transfusions
2018
HLA Class I Alloimmunization and Platelet Transfusion Support in HLA-Identical Bone Marrow Transplant for Sickle Cell Disease: A Sickle Transplant Alliance for Research Study
Nickel R, Horan J, Abraham A, Qayed M, Haight A, Luban N, Hendrickson J. HLA Class I Alloimmunization and Platelet Transfusion Support in HLA-Identical Bone Marrow Transplant for Sickle Cell Disease: A Sickle Transplant Alliance for Research Study. Blood 2018, 132: 3816. DOI: 10.1182/blood-2018-99-114116.Peer-Reviewed Original ResearchBone marrow transplantHLA class ISickle cell diseaseHLA-identical bone marrow transplantsMore platelet transfusionsNon-alloimmunized patientsPlatelet transfusion supportPlatelet transfusionsRBC transfusionClass IPositive PRAPre-BMTTransfusion supportPediatric patientsMarrow transplantCell diseaseBone marrowRed blood cell transfusionHepatic sinusoidal obstruction syndromeApheresis platelet transfusionHLA-disparate donorsBlood cell transfusionSinusoidal obstruction syndromePlatelet transfusion requirementsCord blood graftsInfluenza Infection Induces RBC Alloimmunization By a Type 1 Interferon Dependent Mechanism
Gibb D, Liu D, Liu J, Santhanakrishnan M, Eisenbarth S, Hendrickson J. Influenza Infection Induces RBC Alloimmunization By a Type 1 Interferon Dependent Mechanism. Blood 2018, 132: 743. DOI: 10.1182/blood-2018-99-110884.Peer-Reviewed Original ResearchIFNα/βInfluenza-infected miceRBC alloimmunizationWildtype miceInfluenza infectionTransfusion recipientsRed blood cell transfusionFollicular helper cell differentiationDependent mechanismCompatible blood productsFrequency of alloimmunizationVirus 3 daysBlood cell transfusionIFNα/β productionCertain autoimmune diseasesPro-inflammatory stimuliT cell proliferationInterferon-dependent mechanismRisk of alloimmunizationType 1 interferonLow baseline levelsHelper cell differentiationCell transfusionAlloimmune responseIgG responses6 A Novel Association Between High Red Blood Cell Alloimmunization Rates and Hereditary Hemorrhagic Telangiectasia (HHT)
Zheng Y, Pollak J, Henderson K, Hendrickson J, Tormey C. 6 A Novel Association Between High Red Blood Cell Alloimmunization Rates and Hereditary Hemorrhagic Telangiectasia (HHT). American Journal Of Clinical Pathology 2018, 149: s166-s166. DOI: 10.1093/ajcp/aqx149.375.Peer-Reviewed Original ResearchHereditary hemorrhagic telangiectasiaAlloimmunization rateRBC transfusionHHT patientsHemorrhagic telangiectasiaRed blood cell transfusionFirst RBC transfusionMore RBC transfusionsNon-ABO alloantibodiesProphylactic antigen matchingRBC alloimmunization rateBlood cell transfusionMultiple arteriovenous malformationsStudent's t-testAutosomal dominant disorderCommon alloantibodiesHHT subjectsCell transfusionReferral centerControl patientsMale patientsAntigen matchingRetrospective studyAntibody screenPatient population
2015
North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia
Pine A, Lee E, Sekeres M, Steensma D, Prebet T, DeZern A, Komrokji R, Litzow M, Luger S, Stone R, Erba H, Garcia-Manero G, Lee A, Podoltsev N, Barbarotta L, Hendrickson J, Gore S, Zeidan A. North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. Blood 2015, 126: 1138. DOI: 10.1182/blood.v126.23.1138.1138.Peer-Reviewed Original ResearchRed blood cell transfusionNon-bleeding patientsBlood cell transfusionBone marrow biopsyBlood product transfusionSouthwest Oncology GroupPlatelet transfusionsOutpatient settingAcute leukemiaPlatelet levelsCell transfusionHemoglobin levelsTransfusion practiceLumbar punctureFibrinogen levelsProduct transfusionHospitalized patientsOncology GroupClinical trialsPlatelet thresholdMost respondersConsensus evidence-based guidelinesMost providersEastern Cooperative Oncology GroupStable hospitalized patients
2013
KEL RBC Transfusion Induces IgG Anti-KEL Antibodies Independent Of CD4 T Cells
Stowell S, Girard-Pierce K, Arthur C, Smith N, Zimring J, Hendrickson J. KEL RBC Transfusion Induces IgG Anti-KEL Antibodies Independent Of CD4 T Cells. Blood 2013, 122: 41. DOI: 10.1182/blood.v122.21.41.41.Peer-Reviewed Original ResearchCD4 T cellsMHC class IIRBC alloantibody formationRBC transfusionT cellsKEL RBCsIsotype controlAlloantibody formationC57BL/6 recipientsRBC alloantibodiesRBC alloantigensClass IICD-4 T-cellsCD4 T-cell depletionRed blood cell transfusionCD4 T cell helpMHC class II antigensChronic transfusion therapyBlood cell transfusionT-cell depletionHemolytic transfusion reactionsIsotype control antibodyClass II antigensT cell helpMHC antigen presentationAlloimmunization To HLA Class I Antigens But Not H-Y Antigens Is Associated With Transfusion In Children With Sickle Cell Disease
Nickel R, Hendrickson J, Kean L, Yee M, Bray R, Gebel H, Miklos D, Horan J. Alloimmunization To HLA Class I Antigens But Not H-Y Antigens Is Associated With Transfusion In Children With Sickle Cell Disease. Blood 2013, 122: 39. DOI: 10.1182/blood.v122.21.39.39.Peer-Reviewed Original ResearchHematopoietic stem cell transplantMinor histocompatibility antigensHuman leukocyte antigenSickle cell diseaseHLA class I antibodiesClass I human leukocyte antigenClass I antibodiesPediatric SCD patientsRBC transfusionHLA class IGraft rejectionSCD patientsY antigenHLA antibodiesChronic transfusionIgG antibodiesI antibodiesCell diseaseClass I HLA antibodiesHLA class II antibodiesClass II human leukocyte antigenRed blood cell transfusionManagement of SCDClass IHLA-identical transplantation